Browsing by Subject "retinitis pigmentosa"

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Bilateral intravitreal dexamethasone implant for retinitis pigmentosa-related macular edema
    (S. Karger AG, 2013) Saatci A.O.; Selver O.B.; Seymenoglu G.; Yaman A.
    Purpose: To report the efficacy of intravitreal dexamethasone implant in a patient with retinitis pigmentosa and bilateral cystoid macular edema unresponsive to topical carbonic anhydrase inhibitors. Case Report: A 36-year-old man with bilateral cystoid macular edema associated with retinitis pigmentosa that was unresponsive to topical carbonic anhydrase inhibitors underwent bilateral 0.7-mg intravitreal dexamethasone implants two weeks apart. Spectral domain optical coherence tomography revealed resolution of macular edema one week following each injection in both eyes and his visual acuity improved. However, macular edema recurred two months later in OS and three months later in OD. Second implant was considered for both eyes. No implant-related complication was experienced during the follow-up of seven months. Conclusion: Inflammatory process seems to play a role in retinitis pigmentosa. Intravitreal dexamethasone implant may offer retina specialists a therapeutic option especially in cases unresponsive to other treatment regimens in eyes with retinitis pigmentosa-related macular edema. © 2013 S. Karger AG, Basel.
  • No Thumbnail Available
    Item
    Intravitreal Dexamethasone Implant in Retinitis Pigmentosa-related Cystoid Macular Edema
    (Lippincott Williams and Wilkins, 2018) Mansour A.M.; Sheheitli H.; Kucukerdonmez C.; Sisk R.A.; Moura R.; Moschos M.M.; Lima L.H.; Al-Shaar L.; Arevalo J.F.; Maia M.; Foster R.E.; Kayikcioglu O.; Kozak I.; Kurup S.; Zegarra H.; Gallego-Pinazo R.; Hamam R.N.; Bejjani R.A.; Cinar E.; Erakgün E.T.; Kimura A.; Teixeira A.
    Purpose: To report the clinical outcome after intravitreal dexamethasone implant in patients with retinitis pigmentosa and cystoid macular edema. Methods: Multicenter retrospective case series of eyes with retinitis pigmentosa and cystoid macular edema that underwent intravitreal dexamethasone implant. Primary outcome measures were best-corrected visual acuity in LogMAR and central macular thickness. Statistical analyses used two-tailed comparison with Wilcoxon signed-rank test. Results: There were a total of 45 eyes from 34 patients with a mean age of 32.7 years (range 16-57) and mean follow-up of 15.5 ± 13.0 months. At Month 3 after the first injection, mean initial best-corrected visual acuity improved from 0.61 ± 0.38 (20/81) to 0.37 ± 0.16 (20/47) (P = 0.012), whereas mean central macular thickness (m) decreased from 506 ± 288 m to 311.7 ± 71.6 m (P < 0.001) and mean intraocular pressure increased from 15.7 ± 2.3 mmHg to 19.8 ± 11.0 mmHg (P = 0.01). Fourteen eyes had multiple injections (1-7 reinjections) at a mean interval of 6 months. Treatment effect was durable with multiple injections, but with seven eyes developing visually significant cataracts. Conclusion: Best-corrected visual acuity improved up to 4 months in around half of the eyes. Eyes that benefited the most were pseudophakic, steroid nonresponsive, with large initial central macular thickness, and profuse fluorescein dye leakage. © Ophthalmic Communications Society, Inc.